GlobalData

GlobalData forecasts sugemalimab to generate sales of $31 million (patient-based forecast) by 2030 for T-cell lymphomas in China

The global cell and gene therapy market is expected to reach $80 billion in 2029, with a high CAGR of 51.6 per cent between 2023…

PCSK9 inhibitors, like VERVE-101, currently holds 20 per cent market share in the acute coronary syndrome market. PCSK9 inhibitors…

The COVID-19 pandemic catalysed the adoption of decentralised clinical trials (DCTs) even though they have been in use for…

The drug is forecast to achieve peak sales of $788 million by 2029

Zydus Lifesciences recently entered into a co-marketing partnership with Sun Pharma for desidustat for anemia associated with CKD…

GlobalData identified the influx of several new disease-modifying therapies (DMTs) within the past two years as the main driver of…

This indicates a shift from the conventional IR to the GLP1R as the primary target for pioneering T2D treatments

GSK is also in the process of developing a pentavalent vaccine, and positive Phase III data were announced earlier this year.…

An anticipated 11 assets in the late-stage pipeline will enter the CD market during the forecast period